HRP20150890T1 - Lijeäśenje metastaza na mozgu s inhibitorima receptora endotelina u kombinaciji s citotoksiäśnim kemoterapijskim sredstvom - Google Patents

Lijeäśenje metastaza na mozgu s inhibitorima receptora endotelina u kombinaciji s citotoksiäśnim kemoterapijskim sredstvom Download PDF

Info

Publication number
HRP20150890T1
HRP20150890T1 HRP20150890TT HRP20150890T HRP20150890T1 HR P20150890 T1 HRP20150890 T1 HR P20150890T1 HR P20150890T T HRP20150890T T HR P20150890TT HR P20150890 T HRP20150890 T HR P20150890T HR P20150890 T1 HRP20150890 T1 HR P20150890T1
Authority
HR
Croatia
Prior art keywords
treatment
brain metastases
combination
chemotherapy agent
cytotoxic chemotherapy
Prior art date
Application number
HRP20150890TT
Other languages
English (en)
Croatian (hr)
Inventor
Isaiah J. Fidler
Sun-Jin Kim
Original Assignee
Board Of Regents, The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42938154&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20150890(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Board Of Regents, The University Of Texas System filed Critical Board Of Regents, The University Of Texas System
Publication of HRP20150890T1 publication Critical patent/HRP20150890T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1077—Beam delivery systems
    • A61N5/1084—Beam delivery systems for delivering multiple intersecting beams at the same time, e.g. gamma knives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Environmental Sciences (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
HRP20150890TT 2009-08-10 2010-08-09 Lijeäśenje metastaza na mozgu s inhibitorima receptora endotelina u kombinaciji s citotoksiäśnim kemoterapijskim sredstvom HRP20150890T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23268709P 2009-08-10 2009-08-10
PCT/US2010/044832 WO2011019630A2 (en) 2009-08-10 2010-08-09 Treatment of astrocytes-tumor cells with inhibitors of endothelin receptors
EP10742690.0A EP2464218B1 (en) 2009-08-10 2010-08-09 Treatment of brain metastases with inhibitors of endothelin receptors in combination with a cytotoxic chemotherapy agent

Publications (1)

Publication Number Publication Date
HRP20150890T1 true HRP20150890T1 (hr) 2015-09-25

Family

ID=42938154

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20150890TT HRP20150890T1 (hr) 2009-08-10 2010-08-09 Lijeäśenje metastaza na mozgu s inhibitorima receptora endotelina u kombinaciji s citotoksiäśnim kemoterapijskim sredstvom

Country Status (27)

Country Link
US (2) US8999934B2 (enEXAMPLES)
EP (1) EP2464218B1 (enEXAMPLES)
JP (1) JP2013501791A (enEXAMPLES)
KR (1) KR20120088665A (enEXAMPLES)
CN (1) CN102510719B (enEXAMPLES)
AU (1) AU2010282744B2 (enEXAMPLES)
BR (1) BR112012003103A2 (enEXAMPLES)
CA (1) CA2770397A1 (enEXAMPLES)
CL (1) CL2012000333A1 (enEXAMPLES)
DK (1) DK2464218T3 (enEXAMPLES)
EA (1) EA023864B1 (enEXAMPLES)
ES (1) ES2543280T3 (enEXAMPLES)
HR (1) HRP20150890T1 (enEXAMPLES)
HU (1) HUE026005T2 (enEXAMPLES)
IL (1) IL217915A0 (enEXAMPLES)
IN (1) IN2012DN01261A (enEXAMPLES)
MA (1) MA33571B1 (enEXAMPLES)
MX (1) MX2012001562A (enEXAMPLES)
NZ (1) NZ598078A (enEXAMPLES)
PL (1) PL2464218T3 (enEXAMPLES)
PT (1) PT2464218E (enEXAMPLES)
SG (1) SG178828A1 (enEXAMPLES)
SI (1) SI2464218T1 (enEXAMPLES)
TN (1) TN2012000054A1 (enEXAMPLES)
TW (1) TWI483938B (enEXAMPLES)
WO (1) WO2011019630A2 (enEXAMPLES)
ZA (1) ZA201200980B (enEXAMPLES)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201309298A (zh) * 2011-02-04 2013-03-01 Actelion Pharmaceuticals Ltd 治療惡性神經膠質瘤之醫藥組合物
CA2840170A1 (en) 2011-06-21 2012-12-27 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
SG11201707127VA (en) 2015-03-06 2017-09-28 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation
CA2978679A1 (en) * 2015-03-06 2016-09-15 Beyondspring Pharmaceuticals, Inc. Method of treating a brain tumor
SG10202108194XA (en) 2015-07-13 2021-09-29 Beyondspring Pharmaceuticals Inc Plinabulin compositions
WO2017024032A2 (en) 2015-08-03 2017-02-09 Enb Therapeutics, Llc Compositions and methods for treating cancers associated with etbr activation
JP6996728B2 (ja) * 2016-01-07 2022-01-17 学校法人自治医科大学 グルコーストランスポーター１発現用アデノ随伴ウイルスベクター
RU2753543C1 (ru) 2016-02-08 2021-08-17 Бейондспринг Фармасьютикалс, Инк. Композиции, содержащие тукаресол или его аналоги
JP7122499B2 (ja) * 2016-06-03 2022-08-22 幸久 村田 がん転移阻害剤
CN118304304A (zh) 2016-06-06 2024-07-09 大连万春布林医药有限公司 用于减少中性粒细胞减少症的组合物和方法
EP3565812B1 (en) 2017-01-06 2023-12-27 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
CN110381938A (zh) 2017-02-01 2019-10-25 大连万春布林医药有限公司 减少中性粒细胞缺乏症的方法
KR20190129046A (ko) 2017-02-15 2019-11-19 더 리전트 오브 더 유니버시티 오브 캘리포니아 Nk 세포를 활성화시키기 위한 조성물 및 방법
AU2019206652B2 (en) 2018-01-12 2024-11-14 Enb Therapeutics, Inc. Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation
US11786523B2 (en) 2018-01-24 2023-10-17 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia
CN109232546B (zh) 2018-09-25 2020-09-04 中国人民解放军总医院 一种嘧啶磺酰胺类衍生物的医药用途
WO2020233694A1 (zh) 2019-05-22 2020-11-26 石家庄智康弘仁新药开发有限公司 一种嘧啶磺酰胺类化合物的晶型及其制备方法
CN112062857B (zh) * 2019-06-10 2024-08-09 鸿运华宁（杭州）生物医药有限公司 Eta抗体与bnp的融合蛋白质，及其药物组合物和应用
US20240197723A1 (en) 2021-04-09 2024-06-20 Beyondspring Pharmaceuticals, Inc. Therapeutic compositions and methods for treating tumors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2431675C (en) * 2000-12-18 2011-11-08 Actelion Pharmaceuticals Ltd. Novel sulfamides and their use as endothelin receptor antagonists
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
HRP20120957T1 (hr) * 2005-09-12 2012-12-31 Actelion Pharmaceuticals Ltd. Stabilni farmaceutski sastav koji sadrži pirimidin-sulfamid
KR20100132489A (ko) 2008-02-20 2010-12-17 액테리온 파마슈티칼 리미티드 난소암을 치료하기 위하여 파클리탁셀을 포함하는 조합
TW201309298A (zh) 2011-02-04 2013-03-01 Actelion Pharmaceuticals Ltd 治療惡性神經膠質瘤之醫藥組合物

Also Published As

Publication number Publication date
AU2010282744B2 (en) 2014-08-28
PL2464218T3 (pl) 2015-12-31
MA33571B1 (fr) 2012-09-01
SG178828A1 (en) 2012-04-27
ZA201200980B (en) 2012-10-31
NZ598078A (en) 2013-07-26
PT2464218E (pt) 2015-09-16
SI2464218T1 (sl) 2015-10-30
CN102510719A (zh) 2012-06-20
CN102510719B (zh) 2015-07-22
JP2013501791A (ja) 2013-01-17
EA023864B1 (ru) 2016-07-29
CL2012000333A1 (es) 2013-01-25
US20150352113A1 (en) 2015-12-10
EP2464218A2 (en) 2012-06-20
HUE026005T2 (en) 2016-04-28
EP2464218B1 (en) 2015-05-27
MX2012001562A (es) 2013-01-29
WO2011019630A3 (en) 2011-06-03
HK1171336A1 (en) 2013-03-28
BR112012003103A2 (pt) 2016-04-19
EA201270264A1 (ru) 2013-02-28
KR20120088665A (ko) 2012-08-08
TWI483938B (zh) 2015-05-11
TN2012000054A1 (en) 2013-09-19
ES2543280T3 (es) 2015-08-17
WO2011019630A2 (en) 2011-02-17
TW201109315A (en) 2011-03-16
CA2770397A1 (en) 2011-02-17
US8999934B2 (en) 2015-04-07
IN2012DN01261A (enEXAMPLES) 2015-05-15
DK2464218T3 (en) 2015-07-20
AU2010282744A1 (en) 2012-03-22
IL217915A0 (en) 2012-03-29
US20120144510A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
HRP20150890T1 (hr) Lijeäśenje metastaza na mozgu s inhibitorima receptora endotelina u kombinaciji s citotoksiäśnim kemoterapijskim sredstvom
HRP20200696T1 (hr) Terapija u kombinaciji s inhibitorom topoizomeraze
MY162514A (en) Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
HRP20211177T1 (hr) Korteksolon 17alfa-valerat za uporabu u liječenju tumora
MX2015004644A (es) Compuestos de carbohidratos con funcion de galactosa para el tratamiento de la nefropatia diabetica y de los trastornos asociados.
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2009009304A (es) Inhibidores de cinasa pim y metodos para su uso.
NZ707477A (en) Activin-actrii antagonists and uses for treating bone and other disorders
MX376008B (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
MX2009011843A (es) Dosificacion intravenosa y oral de un inhibidor de p2y12 de accion directa y reversible.
CL2014000833A1 (es) Composicion para ser usada en la promocion del crecimiento de hueso sano y/o en la prevencion y/o tratamiento de la enfermedad osea
PH12016502353A1 (en) Pharmaceutical composition
EP3412668A3 (en) A selective inhibitor of phosphatidylinositol 3-kinase-gamma
MX2016001446A (es) Inhibidores de heterobicicloaril rorc2 y metodos de uso de los mismos.
CL2015003595A1 (es) Inhibidores/antiandrógenos novedosos de cyp17
TW201613577A (en) Pharmaceutical combinations
GB201204263D0 (en) Giloma treatment
TN2013000333A1 (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
MX2015005732A (es) Compuestos tricíclicos y métodos para hacer y utilizar los mismos.
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
IL229424A0 (en) Pharmaceutical preparations containing neuropilin inhibitors and their uses in the prevention and/or treatment of angiogenic disorders and cancer
RS55508B1 (sr) Farmaceutska kompozicija za primenu u tretmanu ili prevenciji deficijencije vitamina i minerala kod pacijenata podvrgnutih operaciji želudačnog bajpasa
IL245998B (en) Pharmaceutical preparations for the treatment of metastatic cancer and its prevention
EA201491010A1 (ru) Варианты остеопонтина для применения в подавлении или предупреждении опухолевого роста и композиции, содержащие такие варианты остеопонтина